Vidac Pharma

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning

Alcresta Inc. Alcresta brings in $49.4m via Series C Alcresta Inc. (therapies for gastrointestinal disorders and rare diseases) raised $49.4m in its Series C financing to new backer Athyrium a